Health Care • Biotechnology: Pharmaceutical Preparations
$28.68 ▲ +0.61
(+2.17%)
MKT CAP: $3.60B • VOL: 905.5K
52W L $11 52W H $41
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
AMLX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $87.4M | $380.8M |
| YoY Revenue Growth % | — | -77.1% | — |
| Gross Profit | — | $81.4M | — |
| Gross Margin % | — | 93.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$153.3M | -$314.7M | $38.8M |
| Operating Margin % | — | -80.0% | 10.2% |
| Net Income (GAAP) | -$144.7M | -$301.7M | $49.3M |
| EBITDA (Normalized) | -$153.2M | -$314.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$123.3M | -$167.6M | $11.9M |
| Capital Expenditures (CapEx) | $138.0K | $157.0K | — |
| Free Cash Flow (FCF) | -$123.5M | -$167.8M | $11.9M |
| FCF Margin % | — | -80.0% | 3.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $226.7M | $77.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $305.3M | $164.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMLX.